Drugs / Candesartan
Candesartan
also known as
candesartan cilexetil · Atacand · Blopress · Candemore · candesartan (Atacand) · Candesartan cilexitil · CND · SPC3001
Trials 67 · started per year
today
1
1
4
1
1
3
4
8
1
5
2
1
2
2
4
2
6
2
1
3
4
2
3
1
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04430959 | Oct 2020 → Jul 2022 | bipolar depression | The University of Texas Health Science Center, Houston | Withdrawn | No outcome recorded Stop: Business |
| Phase 0 | NCT03583866 | May 2018 → Dec 2025 overdue | hypertensive disorder | Augusta University | Active not recruiting | No outcome recorded |
| Phase 18 trials | ||||||
| Phase 1 | NCT04611932 | Nov 2020 → Mar 2021 | cardiovascular disorder | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT04245046 | Jan → Feb 2019 | — | Midas Pharma GmbH | Completed | No outcome recorded |
| Phase 1 | NCT02064621 | Jun → Aug 2014 | hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT02064556 | May → Jul 2014 | hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT02079506 | Feb 2014 | — | Alvogen Korea | Completed | No outcome recorded |
| Phase 1 | NCT00905333 | Oct → Nov 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00310778 | Mar 2006 → Mar 2007 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 1 | NCT02614352 | ? → Feb 2016 | — | Ahn-Gook Pharmaceuticals Co.,Ltd | Unknown | No outcome recorded |
| Phase 1/22 trials · 1 missed | ||||||
| Phase 1/2 | NCT01678794 | Feb 2012 → Jun 2016 | cardio-renal syndrome | Mayo Clinic | Completed | Missed primary |
| Phase 1/2 | NCT00990639 | Sep 2005 → Dec 2008 | alcoholic liver disease | Yonsei University | Completed | No outcome recorded |
| Phase 210 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT07135245 | Jan 2026 → Sep 2030 expected | Alzheimer disease | Rune Skovgaard Rasmussen | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06212648 | Mar → Nov 2022 | essential hypertension | Shin Poong Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04574713 | Apr 2021 → Apr 2024 | migraine disorder | St. Olavs Hospital | Completed | Met primary |
| Phase 2 | NCT03688633 | May 2019 → May 2021 | peripheral neuropathy | University Hospital, Limoges | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02646982 | Jun 2016 → Aug 2020 | cognitive impairment with or without cerebellar ataxia | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT02206165 | Mar 2014 → Apr 2015 | essential hypertension | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 2 | NCT01938664 | Jan 2013 → Jul 2016 | cocaine dependence | Baylor College of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT01434134 | Sep 2011 → Sep 2014 | breast cancer, heart failure | University Hospital, Akershus | Completed | Missed primary |
| Phase 2 | NCT00605072 | Jan 2008 → Dec 2011 | cognitive impairment with or without cerebellar ataxia, hypertensive disorder | University of Southern California | Completed | Mixed |
| Phase 2 | NCT00430833 | — | hypertrophic cardiomyopathy | Charles University, Czech Republic | Unknown | No outcome recorded |
| Phase 2/32 trials · 2 met primary | ||||||
| Phase 2/3 | NCT04351724 | Apr 2020 → Dec 2021 | COVID-19 | Medical University of Vienna | Unknown | Met primary |
| Phase 2/3 | NCT00884663 | Apr 2009 → Mar 2012 | migraine with aura, migraine without aura | Norwegian University of Science and Technology | Completed | Met primary |
| Phase 319 trials · 1 met primary · 6 missed | ||||||
| Phase 3 | NCT05321875 | Jun 2022 → Jun 2026 overdue | dilated cardiomyopathy | Cristina Avendaño Solá | Recruiting | No outcome recorded |
| Phase 3 | NCT04591210 | Jan 2021 → Dec 2024 | COVID-19, cardiovascular disorder | Ottawa Heart Institute Research Corporation | Completed | No outcome recorded |
| Phase 3 | NCT04606563 | Oct 2020 → Apr 2022 | COVID-19 | University of British Columbia | Terminated | Missed primary |
| Phase 3 | NCT02969265 | May 2017 → Jul 2018 | hypertensive disorder | Takeda | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT02521246 | Nov 2016 → May 2017 | essential hypertension | EMS | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT02521233 | Nov 2016 → May 2017 | essential hypertension | EMS | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | Mixed |
| Phase 3 | NCT02770261 | Dec 2015 → Aug 2016 | hyperlipidemia, hypertensive disorder | Alvogen Korea | Completed | No outcome recorded |
| Phase 3 | NCT02651870 | Apr 2015 → Feb 2016 | hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT00867490 | Mar → Aug 2009 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00775840 | Jan → Dec 2008 | diastolic heart failure | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00360178 | Jul → Dec 2006 | hypertensive disorder | Novartis | Completed | Met primary |
| Phase 3 | NCT00294775 | Feb 2006 → Jan 2009 | aortic valve stenosis, atrial fibrillation | Odense University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT00843154 | Dec 2005 → Jul 2008 | heart failure | Takeda | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00120003 | Jun 2005 → Sep 2010 | stroke disorder | Ullevaal University Hospital | Completed | Missed primary |
| Phase 3 | NCT00252720 | Aug 2001 → Feb 2008 | type 1 diabetes mellitus | AstraZeneca | Completed | Missed primary |
| Phase 3 | NCT00252694 | Aug 2001 → Feb 2008 | type 2 diabetes mellitus | AstraZeneca | Completed | Missed primary |
| Phase 3 | NCT00252733 | Jun 2001 → Apr 2008 | type 1 diabetes mellitus | AstraZeneca | Completed | Missed primary |
| Phase 3 | NCT00130975 | Apr 2001 → Sep 2005 | atrial fibrillation | Asker & Baerum Hospital | Completed | Missed primary |
| Phase 417 trials · 1 met primary · 1 missed | ||||||
| Phase 4 | NCT05637853 | Oct 2022 → Aug 2024 overdue | symptomatic heart failure | Göteborg University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05535595 | Nov 2019 → Aug 2021 | hypertensive disorder | Yonsei University | Completed | Met primary |
| Phase 4 | NCT03231982 | Apr 2017 → Apr 2019 | essential hypertension | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 4 | NCT02817360 | Feb 2016 → Dec 2025 overdue | heart disorder, type 2 diabetes mellitus | Martin Huelsmann | Recruiting | No outcome recorded |
| Phase 4 | NCT01794455 | May 2013 → Mar 2015 | depressive disorder, hypertensive disorder | Vanderbilt University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01682564 | Jan 2012 → Oct 2014 | congestive heart failure, hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 4 | NCT00538486 | Feb 2008 → Jun 2009 | hypertensive disorder, obesity disorder | Third Military Medical University | Completed | No outcome recorded |
| Phase 4 | NCT00564057 | Sep 2007 → Sep 2009 | HIV infectious disease, hypertensive disorder | University of Insubria | Unknown | No outcome recorded |
| Phase 4 | NCT00400582 | Nov 2006 → Apr 2010 | heart failure | Montreal Heart Institute | Completed | Missed primary |
| Phase 4 | NCT00775814 | Oct 2006 → Sep 2008 | hypertensive disorder, obesity disorder | Takeda | Completed | No outcome recorded |
| Phase 4 | NCT00319202 | Jun 2006 → Feb 2010 | glucose intolerance, obesity disorder | Fundación Cardiovascular de Colombia | Terminated | No outcome recorded |
| Phase 4 | NCT00348686 | Jun 2006 → Jun 2008 | hypertensive disorder, hypertensive heart disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00108706 | Dec 2004 → Sep 2007 | stroke disorder | City Hospitals Sunderland NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 4 | NCT00356395 | Aug 2003 → Mar 2006 | hypertensive disorder | Gachon University Gil Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00328302 | Sep 2000 → Apr 2006 | type 1 diabetes mellitus | Karolinska University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00587470 | Aug 1998 → Aug 2001 | mitral valve insufficiency | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT00192803 | — | type 2 diabetes mellitus | Rambam Health Care Campus | Unknown | No outcome recorded |
| Phase not applicable7 trials · 1 met primary | ||||||
| — | NCT01444833 | Oct 2008 → Mar 2009 | essential hypertension | Slovak Academy of Sciences | Unknown | No outcome recorded |
| — | NCT00288717 | Feb 2006 → Sep 2007 | hypertensive disorder | Saitama Medical University | Unknown | No outcome recorded |
| — | NCT00154037 | Oct 2005 → Sep 2006 | — | Technical University Dresden | Completed | No outcome recorded |
| — | NCT00154050 | May 2004 → Jul 2006 | peripheral arterial disease | Technical University Dresden | Completed | No outcome recorded |
| — | NCT00141583 | Apr 2004 → Oct 2006 | essential hypertension | St George's, University of London | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00320970 | Aug 2002 → Sep 2004 | diabetic kidney disease, hypertensive disorder | Providence Health & Services | Completed | No outcome recorded |
| — | NCT00530595 | — | cardiovascular disorder | Saitama Medical University | Completed | Met primary |
| Comparator or background therapy46 trials | ||||||
| Phase 0 | NCT02879721 Comparator | Oct 2009 → Dec 2012 | Barrett esophagus | Göteborg University | Completed | No outcome recorded |
| Phase 1 | NCT01976572 Comparator | Oct 2013 → Jan 2014 | chronic kidney disease, hyperphosphatemia | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01806311 Comparator | Dec 2012 → Aug 2013 | hypertensive disorder | HanAll BioPharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01062451 Comparator | May 2009 → Nov 2013 | methamphetamine dependence, substance abuse | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT07064525 Comparator | Dec 2024 → Dec 2025 overdue | advanced heart failure, diabetes mellitus, essential hypertension, moderate heart failure | Shin Poong Pharmaceutical Co. Ltd. | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT03640312 Comparator | Aug 2019 → May 2022 | hypertensive disorder | Washington University School of Medicine | Completed | Missed primary |
| Phase 2 | NCT01984164 Comparator | Aug 2014 → Dec 2018 | cognitive impairment with or without cerebellar ataxia, hypertensive disorder | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT00282178 Comparator | Apr 2005 → Mar 2006 | hypertensive disorder, obesity disorder | Umeå University | Completed | No outcome recorded |
| Phase 2 | NCT00930995 Comparator | — | hepatitis C virus infection | Kaiser Permanente | Withdrawn | No outcome recorded |
| Phase 3 | NCT06646354 Comparator | Apr → May 2025 overdue | essential hypertension, hyperlipoproteinemia | Hyundai Pharm | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT03770702 Comparator | Oct 2018 → Dec 2025 overdue | rheumatoid arthritis | Tanta University | Recruiting | No outcome recorded |
| Phase 3 | NCT03770936 Comparator | Oct 2018 → Oct 2026 expected | fibrotic liver disease | Tanta University | Recruiting | No outcome recorded |
| Phase 3 | NCT00699452 Comparator | May 2009 → Dec 2012 | aortic valve stenosis | University of Helsinki | Unknown | No outcome recorded |
| Phase 3 | NCT00644475 Comparator | Mar 2008 | essential hypertension | University of Pavia | Unknown | No outcome recorded |
| Phase 3 | NCT00459771 Comparator | Jun 2007 → Dec 2013 | breast cancer | The Netherlands Cancer Institute | Completed | No outcome recorded |
| Phase 3 | NCT00150631 Comparator | Nov 2000 → Jan 2004 | hypertensive disorder | Karin Skov | Unknown | No outcome recorded |
| Phase 3 | NCT00000620 Background | Sep 1999 → Jun 2009 | atherosclerosis, coronary artery disorder, hyperlipoproteinemia, hypertensive disorder +1 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | Missed primary |
| Phase 3 | NCT00634309 Comparator | Jun 1999 → May 2003 | congestive heart failure | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00634712 Comparator | Jun 1999 → May 2003 | congestive heart failure | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00634400 Comparator | Mar 1999 → May 2003 | congestive heart failure | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT07687160 Comparator | Sep 2026 → Feb 2028 expected | hypertensive disorder | Ottawa Hospital Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07655440 Comparator | Jul 2026 → Jul 2031 expected | migraine disorder, tinnitus, vestibular disorder | Stanford University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07513883 Background | Mar 2026 → Sep 2028 expected | heart failure | Ziekenhuis Oost-Limburg | Recruiting | No outcome recorded |
| Phase 4 | NCT05169021 Comparator | Dec 2021 → Dec 2024 overdue | stroke disorder | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04394117 Comparator | Jun 2020 → Nov 2021 | COVID-19 | The George Institute | Completed | No outcome recorded |
| Phase 4 | NCT04330300 Comparator | Apr 2020 → Jul 2021 | COVID-19, essential hypertension | National University of Ireland, Galway, Ireland | Suspended | No outcome recorded Stop: Business |
| Phase 4 | NCT04521023 Comparator | Sep 2017 → Jan 2020 | hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 4 | NCT04061824 Comparator | May 2016 → Dec 2018 | hyperlipidemia, hypertensive disorder | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT02200822 Comparator | Jul 2014 → Feb 2019 | heart failure | Hasselt University | Completed | No outcome recorded |
| Phase 4 | NCT01162902 Comparator | Sep 2013 → Jan 2015 | coronary artery disorder | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01629225 Comparator | Jul 2013 → Jul 2015 | essential hypertension | Third Military Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT01827202 Comparator | Dec 2012 → Feb 2016 | chronic kidney disease, hypertensive disorder, proteinuria | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT01377285 Background | Jun 2010 → Dec 2018 | chronic renal failure syndrome | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00741585 Comparator | Sep 2008 → Jun 2018 | chronic kidney disease, essential hypertension, stroke disorder | University of Vigo | Completed | No outcome recorded |
| Phase 4 | NCT00541853 Background | Dec 2007 → Nov 2012 | autosomal dominant polycystic kidney disease | Kyorin University | Unknown | No outcome recorded |
| Phase 4 | NCT00468923 Comparator | May 2007 → Dec 2015 | stroke disorder | Population Health Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT00391846 Background | Oct 2006 → Jan 2009 | left ventricular failure | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00607672 Comparator | Aug 2006 → Aug 2011 | coronary artery disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 4 | NCT00139386 Comparator | Oct 2005 → Apr 2009 | coronary atherosclerosis, essential hypertension | Kumamoto University | Completed | No outcome recorded |
| Phase 4 | NCT00235287 Comparator | Sep 2005 → ? | cardiovascular disorder, chronic kidney disease | Herlev Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00232882 Comparator | Dec 2003 → Apr 2006 | essential hypertension | Montreal Clinical Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT02261116 Comparator | Apr → Aug 2002 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| — | NCT04429633 Comparator | Jul 2019 → Jul 2022 | breast cancer, chemotherapy-induced toxicity | Samsung Medical Center | Unknown | No outcome recorded |
| — | NCT01116180 Comparator | Apr 2010 → Aug 2012 | hypoglycemia, type 1 diabetes mellitus | Louise Faerch | Completed | No outcome recorded |
| — | NCT00863980 Comparator | Apr 2009 → Jul 2013 | acute coronary syndrome, acute myocardial infarction, hypertensive disorder | Kyoto Prefectural University of Medicine | Terminated | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2019-08-28 | Upsher-Smith Laboratories | Regulatory MHLW Approves Additional Indications for CANDESARTAN Tablets and OD Tablets upsher-smith.com ↗
Osaka, Japan – August 28, 2019 – Sawai Pharmaceutical Co., Ltd. (Head office: Osaka, Japan, President: Mitsuo Sawai) today received approval of its partial change application by the Ministry of Health, Labour and Welfare (MHLW) for CANDESARTAN Tablets 2 mg, 4 mg, 8 mg and 12 mg [SAWAI], and CANDESARTAN OD Tablets 2 mg, 4 mg, 8 mg and 12 mg [SAWAI]*. |
| 2018-04-12 | Shin Poong Pharmaceutical Co. Ltd. | Results 칸데암로,에제로수 전국투어심포지움 shinpoong.co.kr ↗
칸데암로정은 우수한 목표혈압 달성률과 반응률을 나타냈고 , 단일제 대비 칸데암로정 고용량에서도 부작용이 경미해 , 고혈압치료에 있어서 주요제품으로 자리매김 할 것으로 기대했다 . |
| 2018-03-12 | Shin Poong Pharmaceutical Co. Ltd. | Results 칸데암로,에제로수 서울권 심포지엄 shinpoong.co.kr ↗
또한 SCI 급 국제학술지인 Clinical Therapeutics 에 등재된 칸데암로 2 상 임상결과를 소개하며 유효성과 안전성이 입증된 복합 제임을 강조했다 . |
| 2018-01-24 | Shin Poong Pharmaceutical Co. Ltd. | Results 항고혈압 복합제 개량신약 칸데암로정 전국투어Symposium개최 shinpoong.co.kr ↗
또한 SCI 급 국제학술지인 Clinical Therapeutics 에 등재된 칸데암로정 2 상 임상결과를 소개하며 유효성과 안정성을 제시했다 , |
All press releases naming this drug 10 releases
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 114 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Candesartan | “The dosages were SPC1001 High (4/2.5/1.25 mg), SPC1001 Mid1 (2.67/1.67/0.83 mg), SPC1001 Mid2 (4/1.25/1.25 mg), SPC1001 Low (2/1.25/0.625 mg), SPC3001 (candesartan 8 mg),...” PMID 41162308 ↗ Oct 2025112“To evaluate the efficacy and safety of amlodipine besylate and candesartan cilexetil administered in a fixed-dose combination tablet versus co-administered as their separate...” NCT03231982 ↗ “One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin,...” NCT04061824 ↗ “Administration of candesartan to patients with biomarker-confirmed initial-stage Alzheimer's disease will decrease levels of amyloid markers, improve cognitive function, and...” NCT07135245 ↗ “Efficacy and Safety of a Fixed-Dose Combination of Candesartan and Rosuvastatin on Blood Pressure and Cholesterol in Patients With Hypertension and Hypercholesterolemia” PMID 31307833 ↗ Jul 2019 “Angiotensin II receptor antagonists ,these medicines have names that end in "sartan".For examples:losartan,candesartan,irbesartan,olmesartan,telmisartan,valsartan” NCT01377285 ↗ “Participants received either a quadpill of candesartan 2 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg or candesartan 8 mg for 12 weeks.” PMID 38584159 ↗ Apr 2024 “If the patient is intolerant to either of these, an angiotensin receptor blocker (ARB)(Candesartan, Losartan, Valsartan) will be introduced.” NCT05637853 ↗ “The aim of this study was to compare the pharmacokinetics (PKs) of candesartan, amlodipine, and atorvastatin FDC versus separate tablets.” PMID 41970000 ↗ Mar 2026 “Candesartan/Hydrochlorothiazide(Candemore Plus® Tab) Versus Candesartan/Amlodipine(Cantabell® Tab) in Hypertensive Patients” NCT04521023 ↗ “The study recommends physicians to select evidence-based ARBs such as candesartan or valsartan or losartan.” NCT04591210 ↗ |
| Known as | Atacand | “treatment with candesartan (Atacand®) 8 mg daily is initiated” NCT00294775 ↗ |
| Known as | Blopress | “Blopress (Candesartan)” NCT00863980 ↗ |
| Known as | Candemore | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01682564 ↗ |
| Known as | candesartan (Atacand) | “candesartan (Atacand)” NCT00000620 ↗ |
| Known as | candesartan cilexetil | “Study to determine the potential pharmacokinetic interaction of candesartan cilexetil, atorvastatin as atorvastatin calcium trihydrate and amlodipine as amlodipine besilate at...” NCT04245046 ↗2“The subjects receive treatment with either the AT1-antagonist candesartan cilexetil, 16 mg daily or placebo for one year.” NCT00150631 ↗ “Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 2 Diabetic Patients With Retinopathy.” NCT00252694 ↗ |
| Known as | Candesartan cilexitil | “Candesartan cilexitil tablets, 16 mg once daily” NCT00884663 ↗ |
| Known as | CND | “The aim of this study was to evaluate the blood pressure-lowering and cholesterol-lowering effects of a fixed-dose combination therapy using candesartan (CND)/rosuvastatin...” PMID 31307833 ↗ Jul 2019 |
| Known as | SPC3001 | “The dosages were SPC1001 High (4/2.5/1.25 mg), SPC1001 Mid1 (2.67/1.67/0.83 mg), SPC1001 Mid2 (4/1.25/1.25 mg), SPC1001 Low (2/1.25/0.625 mg), SPC3001 (candesartan 8 mg),...” PMID 41162308 ↗ Oct 2025 |
| Action | Inhibit | “AT1 receptor blockade with candesartan in acute stroke” NCT00120003 ↗ |
| Route | Oral | “Candesartan will be given orally (4 weeks 8mg/d, titrated to 16 mg/d for another 4 weeks)” NCT00154037 ↗ |